Canada Grants PLC Systems First Patent for RenalGuard(R)

FRANKLIN, Mass., July 27 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced it has been issued a patent for the real-time fluid balancing capabilities provided by RenalGuard(R) from the Canadian Intellectual Property Office (CIPO) in Quebec, Canada. This is the company's first patent for RenalGuard in Canada.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "We are very pleased that this patent has been issued by Canada. This is the first country to fully review the core patents on our RenalGuard platform, and this patent provides us with additional confidence about our pending patent applications for this innovative technology in the U.S., Europe, and Japan."

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that our pending patent applications for RenalGuard may never be approved or issued in the U.S., Europe or Japan, we may not receive necessary regulatory approvals to market our RenalGuard product, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2008, and our other SEC reports.

PLC Systems, PLC Medical Systems, PLC and CO2 Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.

    Contact:  Mary T. Conway
    Conway Communications
    617-244-9682
    mtconway@att.net

SOURCE PLC Systems Inc.